EUVIMEDEUVIMED entdecken
Crossref

The pharmacist as a key member of the kidney care team

Christie Schumacher, Obidiugwu K Duru, Saugar Maripuri, Glenda Roberts, Elizabeth Van Dril

American Journal of Health-System Pharmacy · 11.06.2025 · 82 (12) · 633-634

DOI: 10.1093/ajhp/zxaf050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 08.04.2025. Verfasst von Christie Schumacher und 4 weiteren Autor:innen. Beteiligte Einrichtung: Midwestern University College of Pharmacy, Downers Grove Campus Downers Grove, IL, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 2 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

According to the Centers for Disease Control and Prevention, 1 in 7 adults in the United States is estimated to have chronic kidney disease (CKD) and as many as 9 in 10 adults with some degree of kidney disease are not aware of their condition.1 In addition, CKD is most often not an isolated condition. Cardiovascular-kidney-metabolic (CKM) syndrome is a newly defined condition that highlights the interconnection of obesity, diabetes, CKD, and cardiovascular disease (CVD). A recent American Heart Association advisory aims to address the fragmented care that currently afflicts patients with these conditions.2 The 2023 advisory emphasized the importance of early-life prevention, screening for risk factors, systematically assessing and addressing social determinants of health, interdisciplinary care models, supporting a healthy lifestyle, and early diagnosis and treatment in CKM syndrome. Individuals with CKM syndrome often have multiple chronic conditions and deserve coordinated, holistic care to ensure optimal and timely initiation and management of drug therapies, education and counseling, and improved health outcomes. Many medications used to manage CKM syndrome overlap between specialties, and individuals may not have access to specialty care or may have longer intervals between specialist visits. Pharmacists play a key role in reducing therapeutic inertia by providing more frequent follow-ups and medication education to ensure timely implementation and titration of guideline-directed medical therapy (GDMT) for people with CKD and CKM syndrome.

Schlagwörter

Stichwörter der Autor:innen

cardiovascular-kidney-metabolic syndromechronic kidney diseasecomprehensive medication managementinterdisciplinary carepharmacists

Autor:innen und Institutionen

  • Midwestern University College of Pharmacy, Downers Grove Campus Downers Grove, IL, USA.
  • David Geffen School of Medicine at UCLA Los Angeles, CA, USA.
  • Hennepin Healthcare Minneapolis, MN, USA.
  • Icahn School of Medicine at Mount Sinai New York, NY, USA.
  • University of Illinois Chicago Herbert M. and Carol H. Retzky College of Pharmacy Chicago, IL, USA.

Zitieren

APA

Schumacher, C., Duru, O. K., Maripuri, S., Roberts, G., & Van Dril, E. (2025). The pharmacist as a key member of the kidney care team. American Journal of Health-System Pharmacy, 82(12), 633-634. https://doi.org/10.1093/ajhp/zxaf050

Vancouver

Schumacher C, Duru OK, Maripuri S, Roberts G, Van Dril E. The pharmacist as a key member of the kidney care team. American Journal of Health-System Pharmacy. 2025;82(12):633-634. doi:10.1093/ajhp/zxaf050

BibTeX
@article{Schumacher2025,
  author = {Schumacher, Christie and Duru, Obidiugwu K and Maripuri, Saugar and Roberts, Glenda and Van Dril, Elizabeth},
  title = {The pharmacist as a key member of the kidney care team},
  journal = {American Journal of Health-System Pharmacy},
  year = {2025},
  volume = {82},
  number = {12},
  pages = {633--634},
  doi = {10.1093/ajhp/zxaf050}
}
Kostenlos starten →